Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep is well-positioned for success with their diversified product pipeline and strong leadership, making them a promising investment opportunity for the long-term. However, investors should be aware of potential risks related to stock market volatility and regulatory approval challenges. Overall, with expected positive results from their Phase 3 and Phase 2b trials, Immutep has the potential for significant growth in the future.

Bears say

Immutep is highly reliant on the FDA's pace of evaluating new drugs and their willingness to approve them, making it risky and dependent on external factors. Their positioning as a complementary agent rather than a direct competitor could negatively impact market potential, and there is confusion among experts regarding the drug's mechanism. Additionally, the clinical trials for both NSCLC and HNSCC have small sample sizes, and the data should be interpreted with caution.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.